Related Experiment Video
Updated: Jun 8, 2026
Mouse Microsurgery Infusion Technique for Targeted Substance Delivery into the CNS via the Internal Carotid Artery
Published on: January 31, 2017
Nano to micro delivery systems: targeting angiogenesis in brain tumors
Ariel Gilert1, Marcelle Machluf
1Faculty of Biotechnology and Food Engineering, Technion Israel Institute of Technology, Haifa, Israel. machlufm@tx.technion.ac.il.
Abstract:
Treating brain tumors using inhibitors of angiogenesis is extensively researched and tested in clinical trials. Although anti-angiogenic treatment holds a great potential for treating primary and secondary brain tumors, no clinical treatment is currently approved for brain tumor patients. One of the main hurdles in treating brain tumors is the blood brain barrier - a protective barrier of the brain, which prevents drugs from entering the brain parenchyma. As most therapeutics are excluded from the brain there is an urgent need to develop delivery platforms which will bypass such hurdles and enable the delivery of anti-angiogenic drugs into the tumor bed. Such delivery systems should be able to control release the drug or a combination of drugs at a therapeutic level for the desired time. In this mini-review we will discuss the latest improvements in nano and micro drug delivery platforms that were designed to deliver inhibitors of angiogenesis to the brain.
Insights
Developing novel drug delivery platforms is crucial for brain tumor treatment. These systems aim to overcome the blood-brain barrier, enabling effective delivery of anti-angiogenic drugs to tumors.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Anti-angiogenic therapies show promise for brain tumors but face delivery challenges.
- The blood-brain barrier restricts therapeutic drug entry into the brain parenchyma.
- No approved clinical treatments currently exist for brain tumors using angiogenesis inhibitors.
Purpose of the Study:
- To review recent advancements in nano and micro drug delivery platforms for brain tumors.
- To highlight systems designed to bypass the blood-brain barrier.
- To discuss controlled drug release mechanisms for anti-angiogenic agents.
Main Methods:
- Review of current literature on drug delivery systems for brain tumors.
- Analysis of nano and micro-scale platforms designed to target brain angiogenesis.
- Discussion of strategies for overcoming the blood-brain barrier.
Main Results:
- Various nano and micro delivery platforms are being developed to target brain tumors.
- These platforms aim to facilitate the passage of anti-angiogenic drugs across the blood-brain barrier.
- Controlled release capabilities are a key feature of these advanced delivery systems.
Conclusions:
- Innovative drug delivery platforms are essential for the clinical success of anti-angiogenic therapy in brain tumors.
- Overcoming the blood-brain barrier remains a critical challenge addressed by these new technologies.
- Further development is needed to translate these platforms into approved patient treatments.
